布洛芬_MSDS_作用_用途_布洛芬CAS号【15687-27-1】

Ibuprofen 是 COX-1 和 COX-2 的抑制剂,IC50 值分别为 13 μM 和 370 μM,具有抗炎的活性。

点击显示

1、缓解类风湿关节炎、骨关节炎、脊柱关节病、痛风性关节炎、风湿性关节炎等各种慢性关节炎的急性发作期或持续性的关节肿痛症状，无病因治疗及控制病程的作用。
2、治疗非关节性的各种软组织风湿性疼痛，如肩痛、腱鞘炎、滑囊炎、肌痛及运动后损伤性疼痛等。
3、急性的轻、中度疼痛如：手术后、创伤后、劳损后、原发性痛经、牙痛、头痛等。
4、对成人和儿童的发热有解热作用。

点击显示

[ 描述 ]:

Ibuprofen 是 COX-1 和 COX-2 的抑制剂,IC50 值分别为 13 μM 和 370 μM,具有抗炎的活性。

[ 相关类别 ]:

信号通路 >> 免疫及炎症 >> COX

研究领域 >> 感染

[ 靶点 ]

COX-1:13 μM (IC50)

COX-2:370 μM (IC50)

[体外研究]

布洛芬抑制酶环氧合酶COX-1和COX-2,其将花生四烯酸转化为前列腺素H2(PGH2)。其作用类似于阿司匹林,吲哚美辛和完整细胞,破碎细胞和纯化酶制剂中的所有其他NSAID [1]。布洛芬抑制雄激素非依赖性前列腺肿瘤细胞PC-3和DU-145中NF-κB和IKKα的组成型活化。它使前列腺细胞对电离辐射敏感,并在雄激素敏感的前列腺肿瘤细胞系LNCaP中暴露于TNFα或电离辐射后阻断NF-κB的刺激激活。这两者都不能直接归因于IκB-α激酶的抑制,而是抑制IKKα的上游调节因子[2]。布洛芬通过降低癌细胞的存活发挥抗癌作用。布洛芬比阿司匹林和对乙酰氨基酚更有效,并且与(R)-氟比洛芬和吲哚美辛在膀胱和其他器官细胞系中诱导p75NTR蛋白表达相当[3]。

[体内研究]

布洛芬与环氧合酶的血红素基团反应以防止花生四烯酸转化。事先在体内接触布洛芬可以完全保护环氧合酶免受血小板中阿司匹林的不可逆作用[4]。布洛芬治疗可有效减轻由高重复和高强度(HRHF)任务诱导的成年雌性Sprague-Dawley大鼠模型中的关节炎症和早期关节软骨退变。通过阻断血清C1和2C(胶原蛋白I和II降解的生物标志物)以及胶原蛋白降解与合成(C1,2C/CPII,后者是拼贴II型合成的生物标志物)诱导的比例来增加剂量。由HRHF [5]。

[细胞实验]

使用3-（4,5-二甲基噻唑-2-基）-2,5-二苯基溴化四唑（MTT）测定法估计用NSAID处理（48小时）后每个孔中的细胞数。将MTT标记试剂（终浓度，0.5 mg / mL）加入每种NSAID处理的T24细胞，单独使用ponasterone A的细胞，转染ΔDDp75NTR的细胞加ponasterone A，以及转染ΔICDp75NTR的细胞加ponasterone A（2×在96孔培养板（最终体积，100μL培养基/孔）中培养103个细胞/孔，并在37℃，10％CO 2的潮湿气氛中培养4小时。随后，将细胞与每孔100μL溶解溶液一起温育过夜，并使用微量滴定板读数器在570nm处定量样品。

[动物实验]

在任务执行的第4周结束时，上述动物的亚组每天在饮用水中施用布洛芬（45mg / kg体重）：NC + IBU（n = 10），TR + IBU（n = 11）和HRHF + IBU（n = 15）。 HRHF + IBU动物在12周任务期的剩余时间内（即，布洛芬治疗的8周疗程）继续用布洛芬治疗进行HRHF任务方案。所用剂量低于大鼠胃肠道毒性的最大限度，但已被证明可有效减少慢性炎症。通过每天测量悬浮溶液的初始体积和最终体积之间的差异来跟踪每只动物消耗的含药水量/天。基于这些评估，所有组中平均每周布洛芬剂量相似（48.8±6.3mg / kg体重），布洛芬剂量施用或布洛芬血清水平在治疗组之间没有显着差异。

[参考文献]

[1]. Noreen Y, et al. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998 Jan;61(1):2-7.

[2]. Palayoor ST, et al. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999 Dec 2;18(51):7389-94.

[3]. Khwaja F, et al. Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. Cancer Res. 2004 Sep 1;64(17):6207-13.

[4]. Rao GH, et al. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis. 1983 Jul-Aug;3(4):383-8.

[5]. Driban JB, et al. Joint inflammation and early degeneration induced by high-force reaching are attenuated by ibuprofen in an animal model of work-related musculoskeletal disorder. J Biomed Biotechnol. 2011;2011:691412

[相关活性小分子]

[ 密度 ]:
1.0±0.1 g/cm3

[ 沸点 ]:
319.6±11.0 °C at 760 mmHg

[ 熔点 ]:
77-78 °C(lit.)

[ 分子式 ]:
C₁₃H₁₈O₂

[ 分子量 ]:
206.281

[ 闪点 ]:
216.7±14.4 °C

[ 精确质量 ]:
206.130676

[ PSA ]:
37.30000

[ LogP ]:
3.72

[ 外观性状 ]:
无色,结晶固体

[ 蒸汽压 ]:
0.0±0.7 mmHg at 25°C

[ 折射率 ]:
1.519

[ 储存条件 ]:
-20?C Freezer

[ 稳定性 ]:
Stable. Combustible. Incompatible with strong oxidizing agents.

[ 水溶解性 ]:
insoluble

详细MSDS(安全技术说明书)

CHEMICAL IDENTIFICATION

RTECS NUMBER :: MU6640000

CHEMICAL NAME :: Hydratropic acid, p-isobutyl-

CAS REGISTRY NUMBER :: 15687-27-1

LAST UPDATED :: 199801

DATA ITEMS CITED :: 47

MOLECULAR FORMULA :: C13-H18-O2

MOLECULAR WEIGHT :: 206.31

WISWESSER LINE NOTATION :: QVY&R DIY

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 180 mg/kg/3W-I

TOXIC EFFECTS :: Liver - jaundice, cholestatic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 800 mg/kg

TOXIC EFFECTS :: Behavioral - coma Behavioral - somnolence (general depressed activity) Nutritional and Gross Metabolic - metabolic acidosis

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 1028 mg/kg

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic - changes in potassium Nutritional and Gross Metabolic - metabolic acidosis

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 8 mg/kg

TOXIC EFFECTS :: Behavioral - headache Nutritional and Gross Metabolic - body temperature increase

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 120 mg/kg/W-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - effect, not otherwise specified Skin and Appendages - dermatitis, other (after systemic exposure) Nutritional and Gross Metabolic - body temperature increase

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 480 mg/kg/17D-I

TOXIC EFFECTS :: Liver - hepatitis (hepatocellular necrosis), diffuse Immunological Including Allergic - uncharacterized Nutritional and Gross Metabolic - body temperature increase

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 171 mg/kg

TOXIC EFFECTS :: Behavioral - general anesthetic Vascular - BP lowering not characterized in autonomic section

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 469 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 429 mg/kg

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - respiratory obstruction Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic - metabolic acidosis

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 132 mg/kg/6D-I

TOXIC EFFECTS :: Blood - thrombocytopenia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 96 mg/kg/3D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - diplopia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 636 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 626 mg/kg

TOXIC EFFECTS :: Behavioral - analgesia Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation Nutritional and Gross Metabolic - body temperature decrease

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 740 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Rectal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 530 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in motor activity (specific assay) Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 740 mg/kg

TOXIC EFFECTS :: Behavioral - analgesia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 320 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Gastrointestinal - ulceration or bleeding from stomach

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 395 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Rectal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 620 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in motor activity (specific assay) Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 495 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - hamster

DOSE/DURATION :: 1690 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: 1 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 12 gm/kg/30D-C

TOXIC EFFECTS :: Liver - changes in liver weight Endocrine - changes in thymus weight Blood - hemorrhage

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 32760 mg/kg/26W-I

TOXIC EFFECTS :: Gastrointestinal - ulceration or bleeding from large intestine Kidney, Ureter, Bladder - changes in bladder weight Blood - normocytic anemia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 200 mg/kg/4D-I

TOXIC EFFECTS :: Gastrointestinal - ulceration or bleeding from stomach

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Rectal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 12 gm/kg/30D-C

TOXIC EFFECTS :: Gastrointestinal - other changes Blood - normocytic anemia Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1300 mg/kg/2W-I

TOXIC EFFECTS :: Liver - other changes Liver - changes in liver weight Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 480 mg/kg/30D-I

TOXIC EFFECTS :: Gastrointestinal - ulceration or bleeding from stomach

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 9 gm/kg/90D-I

TOXIC EFFECTS :: Liver - changes in liver weight Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 8 mg/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - menstrual cycle changes or disorders

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 840 mg/kg

SEX/DURATION :: female 8-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 10 mg/kg

SEX/DURATION :: female 21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - other effects to embryo

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 600 mg/kg

SEX/DURATION :: female 3-5 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intrauterine

DOSE :: 2 mg/kg

SEX/DURATION :: female 4 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Rectal

DOSE :: 270 mg/kg

SEX/DURATION :: female 17-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - live birth index (measured after birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Rectal

DOSE :: 891 mg/kg

SEX/DURATION :: female 17-21 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Rectal

DOSE :: 1 gm/kg

SEX/DURATION :: female 17-21 day(s) after conception lactating female 4 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Rectal

DOSE :: 810 mg/kg

SEX/DURATION :: male 60 day(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Rectal

DOSE :: 8100 mg/kg

SEX/DURATION :: male 60 day(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 420 mg/kg

SEX/DURATION :: female 7-13 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1260 mg/kg

SEX/DURATION :: female 7-13 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: Cytogenetic analysis

TYPE OF TEST :: Sister chromatid exchange

MUTATION DATA

TEST SYSTEM :: Rodent - mouse

DOSE/DURATION :: 270 mg/kg

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 393,123,1997 *** REVIEWS *** TOXICOLOGY REVIEW JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 30,23,1992 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4905 No. of Facilities: 82 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 2249 (estimated) No. of Female Employees: 1246 (estimated)

点击显示

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302

[ 警示性声明 ]:
P301 + P312 + P330

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xn:Harmful

[ 风险声明 (欧洲) ]:
R22;R51/53;R63

[ 安全声明 (欧洲) ]:
S36-S61-S36/37

[ 危险品运输编码 ]:
2811

[ WGK德国 ]:
3

[ RTECS号 ]:
MU6640000

[ 包装等级 ]:
III

[ 危险类别 ]:
6.1(b)

[ 海关编码 ]:
2924299090

详细合成路线

布洛芬上游产品

布洛芬下游产品

异丁基苯乙酮经缩合、水解、消除、氧化、中和而得。

点击显示

[ 海关编码 ]: 2916392000

[ 中文概述 ]:
2916392000 布洛芬。监管条件:无。增值税率:17.0%。退税率:9.0%。最低关税:6.5%。普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 丙烯酸、丙烯酸盐或酯应报明包装

[ Summary ]:
2916392000 2-(4-isobutylphenyl)propanoic acid。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。Lowest tariff:6.5%。General tariff:30.0%

Environmental friendly method for urban wastewater monitoring of micropollutants defined in the Directive 2013/39/EU and Decision 2015/495/EU.

J. Chromatogr. A. 1418 , 140-9, (2015)

The fate and removal of organic micropollutants in the environment is a demanding issue evidenced by the recent European policy. This work presents an analytical method for the trace quantification of...

Validation of cyclooxygenase-2 as a direct anti-inflammatory target of 4-O-methylhonokiol in zymosan-induced animal models.

Arch. Pharm. Res. 38 , 813-25, (2015)

4-O-methylhonokiol (MH) is known to inhibit inflammation by partially understood mechanisms. Here, the anti-inflammatory mechanisms of MH were examined using enzymatic, cellular, and animal assays. In...

Probiotic properties of lactic acid bacteria isolated from water-buffalo mozzarella cheese.

Probiotics Antimicrob Proteins 6 , 141-56, (2014)

This study evaluated the probiotic properties (stability at different pH values and bile salt concentration, auto-aggregation and co-aggregation, survival in the presence of antibiotics and commercial...

更多文献

公司名：上海化源世纪贸易有限公司

区域：上海市普陀区

价格：

联系人：徐经理

产品详情：布洛芬

公司名：上海吉至生化科技有限公司

区域：上海市奉贤区

价格：
￥468.0/500g ￥138.0/100g ￥88.0/100mg

联系人：刘佳

产品详情：布洛芬

公司名：上海源溪生物科技有限公司

区域：上海市浦东新区

价格：
￥需询单/1g

联系人：赖经理

产品详情：Ibuprofen

公司名：上海脉铂医药科技有限公司

区域：上海市嘉定区

价格：
￥699.0/5g ￥369.0/1g ￥489.0/1g ￥需询单/1g

联系人：李先生

产品详情：Ibuprofen

公司名：上海阿拉丁生化科技股份有限公司

区域：上海市浦东新区

价格：
￥84.9/100g ￥37.9/25g ￥302.9/500g ￥583.9/1kg

联系人：阿拉丁

产品详情：布洛芬

查看所有供应商请点击：

布洛芬供应商

布洛芬的生物活性是什么？

2018-10-03 10:31:47

布洛芬是一种众所周知的药物，具有镇痛(缓解疼痛)和解热(降低发热)的特性。特别已知其用于缓解关节炎的疼痛。布洛芬在20世纪50年代由英国Stewart Adams博士及其同事发现，于1961年获得专利，并于1969年首次上市。1974年，布洛芬在美国上市。布洛芬片以商品名Advil出售。布洛芬。布...

布洛芬_功效与作用_使用说明书

2018-10-03 15:02:42

什么是布洛芬?布洛芬是一种非甾体类抗炎药(NSAID)。它的作用是减少引起体内炎症和疼痛的激素。布洛芬用于减轻发烧并治疗由许多病症引起的疼痛或炎症，例如头痛，牙痛，背痛，关节炎，月经来潮或轻微损伤。布洛芬用于成年人和至少6个月大的儿童。重要信息布洛芬可以增加您致命的心脏病发作或中风的风险，特别是如...

服用布洛芬的副作用

2018-10-07 11:04:34

通常报道的布洛芬副作用包括：出血，呕吐，贫血，血红蛋白减少，嗜酸性粒细胞增多和高血压。其他副作用包括：上消化道出血，上消化道溃疡，头晕和消化不良。有关不良反应的完整列表，请参见下文。适用于布洛芬：口服胶囊，口服胶囊充液，口服混悬液，口服片剂，口服片剂咀嚼片。其他剂型：静脉注射液。除了需要的效果...

布洛芬的副作用之专业详解

2018-10-07 12:23:11

布洛芬是一种非甾体类抗炎药(NSAID)。它的作用是减少引起体内炎症和疼痛的激素。常见的布洛芬副作用可能包括：胃部不适，轻度胃灼热，恶心，呕吐;腹胀，气，腹泻，便秘;头晕，头痛，紧张;轻度瘙痒或皮疹;要么在你耳边响起。对于医疗专业人士，您需要了解的详细布洛芬副作用专业信息。以下信息适用于布洛芬：复...

布洛芬的禁忌人群有哪些？

2022-04-04 17:46:21

布洛芬常用于减轻中度疼痛如肌肉疼痛、牙痛、关节痛、头痛、神经痛及风湿性、类风湿性关节炎、肩周炎等症，也用于治疗普通感冒或流行性感冒引起的发热。那么，哪些人群不宜服用布洛芬呢？1、孕妇及哺乳期的女性怀孕第3周至第3个月末，是胚胎各器官分化形成时期，属于“致畸高度敏感期”，故此时，无论是布洛芬还是其他...

布洛芬

布洛芬用途

布洛芬作用

布洛芬名称

布洛芬生物活性

布洛芬物理化学性质

布洛芬MSDS

详细MSDS(安全技术说明书)

布洛芬毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

布洛芬安全信息

布洛芬合成路线

详细合成路线

布洛芬上下游产品

布洛芬上游产品

布洛芬下游产品

布洛芬制备

布洛芬海关

布洛芬文献

相关化工产品/化学物质：

相关药品：

推荐生产厂家/供应商：

布洛芬相关知识

相关化合物